References

• Devenny, J.J., Godonis, H.E., Harvey, S.J., Rooney, S., Cullen, M.J., & Pelleymounter, M.A. (2012). Weight loss induced by chronic dapagliflozin treatment is attenuated by compensatory hyper-phagia in diet-induced obese (DIO) rats. Obesity, 20(8), 1645-1652. https://doi.org/10.1038/oby.2012.59 google scholar
• Dhalla, N.S., Temsah, R.M., & Netticadan, T. (2000). Role of oxidative stress in cardiovascular diseases. Journal of Hypertension, 18(6), 655-673. https://doi: 10.1097/00004872-200018060-00002 google scholar
• European Medicine Agency (EMA), Assessment Report-Forxiga. (2020 January 1). Retrieved from https://www.ema.europa.eu/ en/documents/assessment-report/forxiga-epar-public-assess-ment-report_en.pdf google scholar
• European Society of Cardiology (ESC). 2020. Guidelines on dia-betes, pre-diabetes, and cardiovascular diseases developed in collaboration with the European Association for the Study of Diabetes (EASD). The task force for diabetes, pre-diabetes, and cardiovascular diseases of the ESC and the EASD. European Heart Journal, 41, 255-323. https://doi.org/10.1093/eurheartj/ehz486 google scholar
• FDA (2020, January 5). Highlights of prescribing information-Farxiga Retrieved from https://www.accessdata.fda.gov/drug-satfda_docs/label/2014/202293s003lbl.pdf google scholar
• FDA (2020, January 5). Highlights of prescribing information-Farxiga Retrieved from https://www.accessdata.fda.gov/drug-satfda_docs/label/2019/209091s002lbl.pdf google scholar
• Forman, H.J., Zhang, H., & Rinna, A. (2009). Glutathione: Overview of its protective roles, measurement, and biosynthesis. Molecu-lar Aspects of Medicine, 30(1-2), 1-12. https://doi.org/10.1016/j. mam.2008.08.006 google scholar
• Fox, C.S., Coady, S., Sorlie, P.D., Levy, D., Meigs, J.B., D’Agostino, R.B. ... Savage, P.J. (2004). Trends in cardiovascular complications of diabetes. Jama, 292(20), 2495-2499. https://doi.org/10.1001/ jama.292.20.2495 google scholar
• Furman, B.L. (2015). Streptozotocin-induced diabetic models in mice and rats. Current Protocols in Pharmacology, 70(1), 5-47. https://doi.org/10.1002/0471141755.ph0547s70 google scholar
• Gallwitz, B. (2018). The cardiovascular benefits associated with the use of sodium-glucose cotransporter 2 inhibitors-real-world data. European Endocrinology, 14(1), 17. https://doi.org/10.17925/ EE.2018.14.1.17 google scholar
• Gawet, S., Wardas, M., Niedworok, E., & Wardas, P (2004). Malondi-aldehyde (MDA) as a lipid peroxidation marker. Wiadomoscilekar-skie (Warsaw, Poland: 1960), 57(9-10), 453-455. google scholar
• Gomes, A.V., Barnes, J.A., Harada, K., & Potter, J.D. (2004). Role of troponin T in disease. Molecular and Cellular Biochemistry, 263(1), 115-129. https://doi.org/10.1023/B:MCBI.0000041853.20588.a0 google scholar
• Han, S., Hagan, D.L., Taylor, J.R., Xin, L., Meng, W., Biller, S.A., ... Whal-ey, J.M. (2008). Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats. Diabetes, 57(6), 1723-1729. https://doi.org/10.2337/db07-1472 google scholar
• Hussein, A.M., Eid, E.A., Taha, M., Elshazli, R.M., Bedir, R.F., & Lashin, L.S. (2020). Comparative study of the effects of GLP1 analog and SGLT2 inhibitor against diabetic cardiomyopathy in type 2 dia-betic rats: possible underlying mechanisms. Biomedicines, 8(3), 43. https://doi.org/10.3390/biomedicines8030043 google scholar
• Inzucchi, S. E., Zinman, B., Wanner, C., Ferrari, R., Fitchett, D., Hantel, S., ... Johansen, O. E. (2015). SGLT-2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing outcome tri-als. Diabetes and Vascular Disease Research, 12(2), 90-100. https:// doi.org/10.1177/1479164114559852 google scholar
• Jankowski, M., Bissonauth, V., Gao, L., Gangal, M., Wang, D., Da-nalache, B., ... Gutkowska, J. (2010). Anti-inflammatory effect of oxytocin in rat myocardial infarction. Basic Research in Cardiol-ogy, 105(2), 205-218. https://doi.org/10.1007/s00395-009-0076-5 Kato, E.T., Silverman, M.G., Mosenzon, O., Zelniker, T.A., Cahn, A., Furtado, R.H., ... Wiviott, S.D. (2019). Effect of dapagliflozin on heart failure and mortality in type 2 diabetes mellitus. Circula-tion, 139(22), 2528-2536. https://doi.org/10.1161/CIRCULA-TIONAHA.119.040130 google scholar
• Kelly, K.J. (2020, January 3). Dapagliflozin approved to reduce risk for heart failure hospitalization in type 2 diabetes. Retrieved from https://www.jwatch.org/fw115953/2019/10/22/dapagliflozin-approved-reduce-risk-heart-failure. google scholar
• Kıngır, Z.B., Kumral, Z.N.Ö., Çam, M.E., Çilingir, Ö.T., Şekerler, T., Ercan, F., ... Okuyan, B. (2019). Effects of dapagliflozin in experimen-tal sepsis model in rats. Turkish Journal of Trauma & Emergency Surgery, 25(3), 213-221. google scholar
• Liro, A. (1985). Variation in weights of body and internal organs of the field mouse in a gradient of urban habitats. Acta Therio-logica, 30(24), 359-377. google scholar
• Liu, Q., Wang, S., & Cai, L. (2014). Diabetic cardiomyopathy and its mechanisms: role of oxidative stress and damage. Journal of Dia-betes Investigation, 5(6), 623-634. https://doi.org/10.1111/jdi.12250">https://doi.org/10.1111/jdi.12250 Lorenzo-Almoros, A., Tunon, J., Orejas, M., Cortes, M., Egido, J., & Lorenzo, O. (2017). Diagnostic approaches for diabetic cardio-myopathy. Cardiovascular Diabetology, 16(1), 1-14. https://doi. org/10.1186/s12933-017-0506-x google scholar
• Ptaszynska, A., Hardy, E., Johnsson, E., Parikh, S., & List, J. (2013). Effects of dapagliflozin on cardiovascular risk factors. Post-graduate Medicine, 125(3), 181-189. https://doi.org/10.3810/ pgm.2013.05.2667 google scholar
• Rebolledo-Solleiro, D., & Fernandez-Guasti, A. (2018). Influence of sex and estrous cycle on blood glucose levels, body weight gain, and depressive-like behavior in streptozotocin-induced diabetic rats. Physiology & Behavior, 194, 560567. https://doi.org/10.1016/j. physbeh.2018.06.033 google scholar
• Reed, J.W. (2016). Impact of sodium-glucose cotransporter 2 inhibitors on blood pressure. Vascular Health and Risk Manage-ment, 12, 393. https://doi.org/10.2147/VHRM.S111991 google scholar
• Reilly, T.P., Graziano, M.J., Janovitz, E.B., Dorr, T.E., Fairchild, C., Lee, F., ... Tirmenstein, M. (2014). Carcinogenicity risk assessment sup-ports the chronic safety of dapagliflozin, an inhibitor of sodium-glucose co-transporter 2, in the treatment of type 2 diabetes mellitus. Diabetes Therapy, 5(1), 73-96. https://doi.org/10.1007/ s13300-014-0053-3 google scholar
• Sehnert, A.J., Huq, A., Weinstein, B.M., Walker, C., Fishman, M., & Stainier, D.Y. (2002).Cardiac troponin T is essential in sarcomere as-sembly and cardiac contractility. Nature Genetics, 31(1), 106-110. https://doi.org/10.1038/ng875 google scholar
• Singh, V.P., Le, B., Khode, R., Baker, K.M., & Kumar, R. (2008). Intracel-lular angiotensin II production in diabetic rats is correlated with cardiomyocyte apoptosis, oxidative stress, and cardiac fibrosis. Di-abetes, 57(12), 3297-3306. https://doi.org/10.2337/db08-0805 Skovs0, S. (2014). Modeling type 2 diabetes in rats using high fat diet and streptozotocin. Journal of Diabetes Investigation, 5(4), 349-358. https://doi.org/10.1111/jdi.12235 google scholar
• Tanajak, P., Sa-Nguanmoo, P., Sivasinprasasn, S., Thummasorn, S., Siri-Angkul, N., Chattipakorn, S.C., & Chattipakorn, N. (2018). Car-dioprotection of dapagliflozin and vildagliptin in rats with cardiac ischemia-reperfusion injury. Journal of Endocrinology, 236(2), 6984. https://doi.org/10.1530/JOE-17-0457 google scholar
• Thomson, S.C., Rieg, T., Miracle, C., Mansoury, H., Whaley, J., Vallon, V., & Singh, P. (2012). Acute and chronic effects of SGLT2 block-ade on glomerular and tubular function in the early diabetic rat. American Journal of Physiology-Regulatory, Integrative and Comparative Physiology, 302(1), R75-R83. https://doi.org/10.1152/ ajpregu.00357.2011 google scholar
• Tiwari, B.K., Pandey, K.B., Abidi, A.B., & Rizvi, S.I. (2013). Markers of oxidative stress during diabetes mellitus. Journal of Biomark-ers, 2013. https://doi.org/10.1155/2013/378790 google scholar
• Wallace, K.B., Hausner, E., Herman, E., Holt, G.D., Macgregor, J.T., Metz, A.L., ... York, M. J. (2004). Serum troponins as biomarkers of drug-induced cardiac toxicity. Toxicologic Pathology, 32(1), 106121. https://doi.org/10.1080/01926230490261302 google scholar
• Wei, W., Liu, Q., Tan, Y., Liu, L., Li, X., & Cai, L. (2009). Oxidative stress, diabetes, and diabetic complications. Hemoglobin, 33(5), 370-377. https://doi.org/10.3109/03630260903212175 google scholar
• Wiviott, S.D., Raz, I., Bonaca, M.P., Mosenzon, O., Kato, E.T., Cahn, A., ... Sabatine, M.S. (2019). Dapagliflozin and cardiovascular out-comes in type 2 diabetes. New England Journal of Medicine, 380(4), 347-357. https://doi.org/10.1056/NEJMoa1812389 google scholar
• Zhang, M., Zhang, H., Liu, C., Li, X., Ling, M., Wang, Z., & Xing, Y. (2018). Myocardial protective effects of nicorandil on rats with type 2 diabetic cardiomyopathy. Medical Science Monitor Basic Re-search, 24, 141. https://doi.org/10.12659/MSMBR.910974 google scholar

Citations